Search results
Chest Radiograph Screening for Detecting Subclinical Tuberculosis in Asymptomatic Household...
Centers for Disease Control and Prevention· 2 days agoDetecting Subclinical Tuberculosis, Peru
Addison's disease: Symptoms, causes, treatment, and more
Medical News Today· 5 days agoAddison’s disease occurs when the adrenal glands do not produce enough of two steroid hormones...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. -...
Benzinga· 5 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech ALVO, today announced the availability of SIMLANDI (adalimumab-ryvk) injection ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 5 days agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
WKRN Nashville· 2 days agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 4 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically ...
The campaigners who fought for justice, but didn't live to see it
BBC via Yahoo News· 7 days agoSteve worked as a teacher, Su as a social worker. But Steve started to develop the symptoms of a...
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Zacks via Yahoo Finance· 5 days agoGilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in...
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance...
NBC 17 Raleigh· 5 days agoCelltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) in adult patients with moderately to severely ...